Spotlight Correspondence
Leukemia (2005) 19, 1985–1987. doi:10.1038/sj.leu.2403928; published online 25 August 2005
Imatinib dose increase up to 1200 mg daily can induce new durable complete cytogenetic remissions in relapsed Ph+ chronic myeloid leukemia patients
R G Piazza1,2, V Magistroni1, F Andreoni1, A Franceschino2, L Tornaghi3, M Varella-Garcia4, S Bungaro5, F Colnaghi5, G Corneo3, E M Pogliani3 and C Gambacorti-Passerini1,3,6
- 1Department of Experimental Oncology, National Cancer Institute, Milan, Italy
- 2University of Milano Bicocca, S Gerardo Hospital, Monza, Italy
- 3Section of Hematology, S Gerardo Hospital, Monza, Italy
- 4Cancer Center, University of Colorado Health Sciences Center, Denver, CO, USA
- 5M Tettamanti Research Center, Pediatric Clinic, University of Milano Bicocca, Monza, Milan, Italy
- 6Department of Oncology, McGill University, Montreal, Canada
Correspondence: Professor C Gambacorti-Passerini, Department of Experimental Oncology, National Cancer Institute, Via Venezian 1, 20133, Milan, Italy; Fax: + 39 2 2390 3237; E-mail: carlo.gambacorti@unimib.it
Received 24 March 2005; Accepted 26 July 2005; Published online 25 August 2005.
Top of page
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated
